Spironolactone and colitis: Increased mortality in rodents and in humans

Inflammatory Bowel Diseases

Volumn 18, Issue 7, 2012, Pages 1315-1324

  Johnson, Laura A ^a   Govani, Shail M ^a   Joyce, Joel C ^b   Waljee, Akbar K ^a   Gillespie, Brenda W ^a   Higgins, Peter D R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Clostridium difficile; Colitis; Crohn's disease; Mortality; Spironolactone

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ENTERITIS; EUROPE; FEMALE; FIBROGENESIS; HOSPITAL PATIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINAL FIBROSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RODENT; UNITED STATES;

ALDOSTERONE ANTAGONISTS; ANIMALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; CROHN DISEASE; FEMALE; FIBROSIS; HOSPITALIZATION; HUMANS; INFLAMMATION; INTESTINAL DISEASES; MALE; MIDDLE AGED; MYOFIBROBLASTS; RATS; RETROSPECTIVE STUDIES; SPIRONOLACTONE; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID;

EID: 84862228291     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21929     Document Type: Article

References (35)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341:709-717. (Pubitemid 29407370)
2. Tox U, Steffen HM. Impact of inhibitors of the Renin-Angiotensin- aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem. 2006;13:3649-3661. (Pubitemid 44873736)
3. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38:635-638.
4. Rajagopalan S, Pitt B. Aldosterone as a target in congestive heart failure. Med Clin North Am. 2003;87:441-457. (Pubitemid 36384090)
5. Gullulu M, Akdag I, Kahvecioglu S, et al. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well. Ren Fail. 2006;28:509-514. (Pubitemid 44277677)
6. Ersoy R, Celik A, Yilmaz O, et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int. 2007;27:424-431. (Pubitemid 47202195)
7. Nishimura H, Ito Y, Mizuno M, et al. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol. 2008;294:F1084-1093.
8. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28: 255-281, vii. (Pubitemid 29306479)
9. Sands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003;98:2712-2718. (Pubitemid 38020113)
10. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782. (Pubitemid 33096034)
11. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol. 1999;277: C183-201. (Pubitemid 29415032)
12. Thannickal VJ, Lee DY, White ES, et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem. 2003;278: 12384-12389. (Pubitemid 36800223)
13. Huang EH, Johnson LA, Eaton K, et al. Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice. Dig Dis Sci. 2010;55:3086-3094.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408. (Pubitemid 34164012)
15. Kim K, Johnson LA, Jia C, et al. Noninvasive ultrasound elasticity imaging (UEI) of Crohn's disease: animal model. Ultrasound Med Biol. 2008;34:902-912. (Pubitemid 351697605)
16. Higgins PD, Johnson LA, Luther J, et al. Prior Helicobacter pylori infection ameliorates Salmonella typhimurium-induced colitis: mucosal crosstalk between stomach and distal intestine. Inflamm Bowel Dis. 2011;17:1398-1408.
17. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33: 464-470. (Pubitemid 32119037)
18. Semler DE, Chengelis CP, Radzialowski FM. The effects of chronic ingestion of spironolactone on serum thyrotropin and thyroid hormones in the male rat. Toxicol Appl Pharmacol. 1989;98:263-268. (Pubitemid 19122373)
19. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. (Pubitemid 17055592)
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
21. Ochs HR, Greenblatt DJ, Bodem G, et al. Spironolactone. Am Heart J. 1978;96:389-400. (Pubitemid 9005214)
22. Overdiek HW, Hermens WA, Merkus FW. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther. 1985;38: 469-474. (Pubitemid 16250325)
23. Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology. 1992;102:1680-1685.
24. Patel SM, Stashefsky E, Maroun MC, et al. The impact of angiotensin- converting enzyme inhibitors and angiotensin-receptor blockers in patients with Clostridium difficile infection. Med Hypotheses. 2011; 76:813-815.
25. Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in Clostridium difficile-associated disease: past and present perspectives. Gut Microbes. 2010;1:58-64.
26. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009;458:1176-1179.
27. Lyerly DM, Saum KE, MacDonald DK, et al. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun. 1985; 47:349-352. (Pubitemid 15169828)
28. Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467:711-713.
29. Witteck A, Yao Y, Fechir M, et al. Rho protein-mediated changes in the structure of the actin cytoskeleton regulate human inducible NO synthase gene expression. Exp Cell Res. 2003;287: 106-115. (Pubitemid 36683206)
30. Chun TY, Bloem LJ, Pratt JH. Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology. 2003; 144:1712-1717. (Pubitemid 36543307)
31. Ibrahim MA, Ashour OM, Ibrahim YF, et al. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009;60:373-381.
32. Fan Q, Liao J, Kobayashi M, et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant. 2004; 19:3012-3020. (Pubitemid 40057622)
33. Tian B, Liu J, Bitterman P, et al. Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB. Am J Physiol Heart Circ Physiol. 2003;285:H1105-1112. (Pubitemid 37048166)
34. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353. (Pubitemid 34062235)
35. Jarvis WR, Schlosser J, Jarvis AA, et al. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control. 2009;37:263-270.